Free Content Modulation of drug sensitivity in yeast cells by the ATP-binding domain of human DNA topoisomerase IIalpha

Authors: Nathalie Vilain; Monika Tsai-Pflugfelder1; Audrey Benoit2; Susan M. Gasser1; Didier Leroy3

Source: Nucleic Acids Research, Volume 31, Number 19, 01 October 2003 , pp. 5714-5722(9)

Publisher: Oxford University Press

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Epipodophyllotoxins are effective antitumour drugs that trap eukaryotic DNA topoisomerase II in a covalent complex with DNA. Based on DNA cleavage assays, the mode of interaction of these drugs was proposed to involve amino acid residues of the catalytic site. An in vitro binding study, however, revealed two potential binding sites for etoposide within human DNA topoisomerase IIalpha (htopoIIalpha), one in the catalytic core of the enzyme and one in the ATP-binding N-terminal domain. Here we have tested how N-terminal mutations that reduce the affinity of the site for etoposide or ATP affect the sensitivity of yeast cells to etoposide. Surprisingly, when introduced into full-length enzymes, mutations that lower the drug binding capacity of the N-terminal domain in vitro render yeast more sensitive to epipodophyllotoxins. Consistently, when the htopoIIalpha N-terminal domain alone is overexpressed in the presence of yeast topoII, cells become more resistant to etoposide. Point mutations that weaken etoposide binding eliminate this resistance phenotype. We argue that the N-terminal ATP-binding pocket competes with the active site of the holoenzyme for binding etoposide both in cis and in trans with different outcomes, suggesting that each topoisomerase II monomer has two non-equivalent drug-binding sites.

Document Type: Research article

DOI: 10.1093/nar/gkg737

Affiliations: 1: Department of Molecular Biology and 2: NCCR Frontiers in Genetics, University of Geneva, Quai Ernest-Ansermet 30, CH-1211 Geneva, Switzerland and 3: *To whom correspondence should be addressed at NCCR Frontiers in Genetics, University of Geneva, Quai Ernest-Ansermet 30, CH-1211 Geneva, Switzerland. didier.leroy@frontiers-in-genetics.org, Tel: +41 22 379 65 90, Fax: +41 22 379 68 68

Free content The full text is free.

View now:
download Modulation of drug sensitivity in yeast cells by the ATP-binding domain of human DNA topoisomerase IIalpha

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A